232 related articles for article (PubMed ID: 37532777)
1. Skp2-mediated MLKL degradation confers cisplatin-resistant in non-small cell lung cancer cells.
Zhou H; Zhou L; Guan Q; Hou X; Wang C; Liu L; Wang J; Yu X; Li W; Liu H
Commun Biol; 2023 Aug; 6(1):805. PubMed ID: 37532777
[TBL] [Abstract][Full Text] [Related]
2. SIRT2 inhibits non-small cell lung cancer cell growth through impairing Skp2-mediated p27 degradation.
Li Z; Huang J; Yuan H; Chen Z; Luo Q; Lu S
Oncotarget; 2016 Apr; 7(14):18927-39. PubMed ID: 26942878
[TBL] [Abstract][Full Text] [Related]
3. Skp2 regulates non-small cell lung cancer cell growth by Meg3 and miR-3163.
Su L; Han D; Wu J; Huo X
Tumour Biol; 2016 Mar; 37(3):3925-31. PubMed ID: 26482610
[TBL] [Abstract][Full Text] [Related]
4. Phytochemical library screening reveals betulinic acid as a novel Skp2-SCF E3 ligase inhibitor in non-small cell lung cancer.
He DH; Chen YF; Zhou YL; Zhang SB; Hong M; Yu X; Wei SF; Fan XZ; Li SY; Wang Q; Lu Y; Liu YQ
Cancer Sci; 2021 Aug; 112(8):3218-3232. PubMed ID: 34080260
[TBL] [Abstract][Full Text] [Related]
5. TRIM17-mediated ubiquitination and degradation of RBM38 promotes cisplatin resistance in non-small cell lung cancer.
Zhong T; Zhang J; Liu X; Li H
Cell Oncol (Dordr); 2023 Oct; 46(5):1493-1507. PubMed ID: 37219768
[TBL] [Abstract][Full Text] [Related]
6. Amplification and overexpression of SKP2 are associated with metastasis of non-small-cell lung cancers to lymph nodes.
Yokoi S; Yasui K; Mori M; Iizasa T; Fujisawa T; Inazawa J
Am J Pathol; 2004 Jul; 165(1):175-80. PubMed ID: 15215173
[TBL] [Abstract][Full Text] [Related]
7. Skp2-mediated ubiquitination and mitochondrial localization of Akt drive tumor growth and chemoresistance to cisplatin.
Yu X; Wang R; Zhang Y; Zhou L; Wang W; Liu H; Li W
Oncogene; 2019 Dec; 38(50):7457-7472. PubMed ID: 31435020
[TBL] [Abstract][Full Text] [Related]
8. FAM60A promotes cisplatin resistance in lung cancer cells by activating SKP2 expression.
Hou Q; Jiang Z; Li Y; Wu H; Yu J; Jiang M
Anticancer Drugs; 2020 Sep; 31(8):776-784. PubMed ID: 32796403
[TBL] [Abstract][Full Text] [Related]
9. Loss of Scribble confers cisplatin resistance during NSCLC chemotherapy via Nox2/ROS and Nrf2/PD-L1 signaling.
Wang N; Song L; Xu Y; Zhang L; Wu Y; Guo J; Ji W; Li L; Zhao J; Zhang X; Zhan L
EBioMedicine; 2019 Sep; 47():65-77. PubMed ID: 31495720
[TBL] [Abstract][Full Text] [Related]
10. Pecanex functions as a competitive endogenous RNA of S-phase kinase associated protein 2 in lung cancer.
Li J; Tian H; Pan J; Jiang N; Yang J; Zhou C; Xu D; Meng X; Gong Z
Cancer Lett; 2017 Oct; 406():36-46. PubMed ID: 28789966
[TBL] [Abstract][Full Text] [Related]
11. Long non‑coding RNA LUCAT1 contributes to cisplatin resistance by regulating the miR‑514a‑3p/ULK1 axis in human non‑small cell lung cancer.
Shen Q; Xu Z; Xu S
Int J Oncol; 2020 Oct; 57(4):967-979. PubMed ID: 32945379
[TBL] [Abstract][Full Text] [Related]
12. miR-1297 Promotes Cell Proliferation of Non-Small Cell Lung Cancer Cells: Involving in PTEN/Akt/Skp2 Signaling Pathway.
Bu W; Luo T
DNA Cell Biol; 2017 Nov; 36(11):976-982. PubMed ID: 28872922
[TBL] [Abstract][Full Text] [Related]
13. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
[TBL] [Abstract][Full Text] [Related]
14. Regulation of p27 by S-phase kinase-associated protein 2 is associated with aggressiveness in non-small-cell lung cancer.
Osoegawa A; Yoshino I; Tanaka S; Sugio K; Kameyama T; Yamaguchi M; Maehara Y
J Clin Oncol; 2004 Oct; 22(20):4165-73. PubMed ID: 15483027
[TBL] [Abstract][Full Text] [Related]
15. N-myc downstream regulated gene 1(NDRG1) promotes the stem-like properties of lung cancer cells through stabilized c-Myc.
Wang Y; Zhou Y; Tao F; Chai S; Xu X; Yang Y; Yang Y; Xu H; Wang K
Cancer Lett; 2017 Aug; 401():53-62. PubMed ID: 28456659
[TBL] [Abstract][Full Text] [Related]
16. Self-targeted knockdown of CD44 improves cisplatin sensitivity of chemoresistant non-small cell lung cancer cells.
Quan YH; Lim JY; Choi BH; Choi Y; Choi YH; Park JH; Kim HK
Cancer Chemother Pharmacol; 2019 Mar; 83(3):399-410. PubMed ID: 30515553
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of miR-101 contributes to epithelial-mesenchymal transition in cisplatin resistance of NSCLC cells by targeting ROCK2.
Ye Z; Yin S; Su Z; Bai M; Zhang H; Hei Z; Cai S
Oncotarget; 2016 Jun; 7(25):37524-37535. PubMed ID: 27229528
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of TRIM65 inhibits autophagy and cisplatin resistance in A549/DDP cells by regulating miR-138-5p/ATG7.
Pan X; Chen Y; Shen Y; Tantai J
Cell Death Dis; 2019 Jun; 10(6):429. PubMed ID: 31160576
[TBL] [Abstract][Full Text] [Related]
19. MLKL-PITPα signaling-mediated necroptosis contributes to cisplatin-triggered cell death in lung cancer A549 cells.
Jing L; Song F; Liu Z; Li J; Wu B; Fu Z; Jiang J; Chen Z
Cancer Lett; 2018 Feb; 414():136-146. PubMed ID: 29104146
[TBL] [Abstract][Full Text] [Related]
20. Elevation of FGD5-AS1 contributes to cell progression by improving cisplatin resistance against non-small cell lung cancer cells through regulating miR-140-5p/WEE1 axis.
Fu J; Cai H; Wu Y; Fang S; Wang D
Gene; 2020 Sep; 755():144886. PubMed ID: 32534055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
